Latest Commercial Revenue News

Page 3 of 8
Temple & Webster delivered record FY26 revenue of $664.6 million and lifted underlying EBITDA by 28%, despite a sharp fall in statutory profit after tax. The online retailer is targeting EBITDA of $33 million to $40 million in FY27 as improved margins, exclusive products and adjacent categories do more of the heavy lifting.
Victor Sage
Victor Sage
29 Sept 2026
Structural Monitoring Systems (ASX:SMN) delivered record FY26 revenue, a sharp lift in profit and $6.0 million of free cash flow as its avionics business outpaced contract manufacturing. The balance sheet is now free of bank debt, but the next leg of the story still depends on FAA approvals and converting CVM technology into commercial revenue.
Victor Sage
Victor Sage
29 Sept 2026
Spacetalk Limited (ASX:SPA) has posted a sharply deeper FY26 loss and negative net assets, while its auditor flagged a material uncertainty over the company’s ability to continue as a going concern. The company says a $10 million post-year-end placement, note conversions and new telco agreements give its software-led strategy room to execute.
Victor Sage
Victor Sage
28 Sept 2026
AnteoTech reduced its FY2026 loss and strengthened its balance sheet, but auditors warned that a material uncertainty remains over the company’s ability to continue as a going concern. Commercial revenue fell sharply as battery and diagnostics opportunities remained largely in evaluation or negotiation.
Victor Sage
Victor Sage
28 Sept 2026
Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.
Ada Torres
Ada Torres
23 Sept 2026
Vulcan Energy has started commercial-scale production in Germany of VULSORB, the proprietary adsorbent at the centre of its planned direct lithium extraction process. The material will supply first-fill volumes for Project Lionheart, although lithium production remains targeted for the second half of 2028.
Victor Sage
Victor Sage
21 Sept 2026
Epiminder has enrolled the 75th patient in its DETECT study, meeting its September target as the US site network expands to 21 centres. The company expects to reach 100 enrolments in November and remains focused on completing the 210-patient study by the end of the first half of calendar 2027.
Ada Torres
Ada Torres
17 Sept 2026
ION Video has secured an oversubscribed $4.25 million placement to fund independent trials of its video technology, with directors and management committing a further $1.2 million subject to shareholder approval. The capital will be used to test whether ION’s architecture can deliver measurable technical and financial benefits in real operating environments.
Sophie Babbage
Sophie Babbage
16 Sept 2026
OncoSil Medical has secured $5.6 million from its three largest institutional investors to fund commercial launches of its OncoSil device in the United States and Australia. The commitments follow FDA and TGA approvals and would lift pro-forma cash to $12.1 million once completed.
Ada Torres
Ada Torres
7 Sept 2026
HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.
Ada Torres
Ada Torres
28 Aug 2026
Artrya Limited marked its first full year of US commercial operations with a $25.18 million loss, driven by regulatory clearances, customer contracts, and an $80 million capital raise.
Ada Torres
Ada Torres
19 Aug 2026
Temple & Webster defied a tough consumer backdrop to post record FY26 revenue of A$665 million and is targeting a substantial 50-80% EBITDA increase in FY27 under new CEO Susie Sugden.
Logan Eniac
Logan Eniac
19 Aug 2026

Browse the archive

Full archive